查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
年龄相关性黄斑变性市场规模、份额和趋势分析报告：按产品（Eilea、Lucentis、Beov）、疾病类型（湿性 AMD、干性 AMD）、分销渠道、地区、细分市场、预测 2022-2030
市场调查报告书
商品编码
1122210

年龄相关性黄斑变性市场规模、份额和趋势分析报告：按产品（Eilea、Lucentis、Beov）、疾病类型（湿性 AMD、干性 AMD）、分销渠道、地区、细分市场、预测 2022-2030

Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

年龄相关性黄斑变性市场增长和趋势

根据 Grand View Research, Inc 的一项新研究，到 2030 年，全球与年龄相关的黄斑变性市场预计将达到 179.9 亿美元。预计从 2022 年到 2030 年，其复合年增长率为 6.9%。这种增长的背后是对新产品开发、产品发布、年龄相关性黄斑变性 (AMD) 患病率上升以及人口老龄化的高额研发投资。

在湿性（渗出性）和干性（干性）年龄相关性黄斑变性中，干性 AMD 是较常见的眼部疾病，85-90% 的病例因视网膜玻璃膜疣过多而导致视力受损。根据美国国家眼科研究所的统计，到 2020 年，美国进行性年龄相关性黄斑变性的患病率约为 300 万。

目前还没有批准用于治疗干性年龄相关性黄斑变性的药物。这为市场参与者提供了解决干性 AMD 患者未满足的医疗需求的机会。然而，对于湿性 AMD，抗 VEGF 药物用于治疗和预防病情进一步恶化。

然而，在湿性 AMD 的情况下，使用抗 VEGF 药物进行治疗，但由于频繁的医院就诊和较短的给药间隔，患者倾向于在治疗完成前停止治疗。主要公司正在研究和开髮长效抗 VEGF 製剂以满足不断增长的需求。2020 年 2 月，Novartis AG获得欧盟委员会批准其黄斑变性治疗药物 Beov 用于治疗年龄相关性黄斑变性。这种药物是一种长效药物，第一年每隔 12 週给药一次。

2022 年 1 月，F. Hoffmann-La Roche Ltd. 的候选药物 Bavismo (falisimab) 将在美国获得批准，用于治疗年龄相关性黄斑变性。获得FDA批准。此外，2021年10月，Roche's Susvimo获得FDA批准，预计2022年进入美国。这是一种专为 LUCENTIS 给药而设计的可再填充植入物，可再填充寿命为 6 个月。所有这些因素预计将在预测期内推动市场增长。

EYLEA 在美国的专利到期日为 2023 年，在欧洲为 2025 年，具体取决于几个专利类别。Lucentis (F. Hoffmann La Roche Ltd.) 于 2020 年 6 月在美国失去专利，并将于 2022 年在欧洲失去专利保护。因此，生物仿製药製造商正在利用这个机会进入 AMD 市场。例如，2021 年 10 月，Formycon AG 和 Bioeq AG 获得了美国 FDA 对其 Lucentis 生物仿製药 BLA 的认可。PDUFA 审查申请的截止日期定于 2022 年 8 月。所有这些因素都可能阻碍预测期内的市场增长。

年龄相关性黄斑变性市场报告亮点

按产品划分，由于市场渗透率高和专利保护，Eylea 在 2021 年占据了最大的收入份额。Biob由于其专利保护和出色的干燥效果，预计在预测期内增长最快

按疾病类型划分，由于 Eylea、Lucentis 和 Beovu 等领先的抗 VEGF 产品的上市，湿性 AMD 将在 2021 年占据最大份额。

北美将在 2021 年占据最大的市场份额，预计在预测期内将继续占据主导地位，因为有更好的报销设施和大量采用新的老年性黄斑变性药物进行治疗

通过分销渠道，专业药房预计在预测期内增长最快，因为製造商正在与他们合作推销他们的产品。

目录

第一章 调查方法和范围

  • 市场细分
    • 估计/预测时间表
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 第一次调查的内容
    • 主要信息列表
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：使用自下而上的方法进行国别市场估算
  • 全球市场：复合年增长率计算
  • 调查假设
  • 二级信息列表
  • 缩略语表
  • 目的

第二章执行摘要

  • 市场概况

第三章市场变量、趋势和范围

  • 市场系列展望
    • 母公司的市场前景
  • 监管框架
  • 绘製渗透率和增长前景
  • 按阶段进行管道分析
    • 主要即将推出的产品
  • 市场动态
    • 市场驱动力分析
    • 市场约束分析
  • PESTEL 分析
  • 市场化管理途径的质量分析
    • 在玻璃体内
    • 其他
  • 流行病学分析
  • 未满足需求分析

第 4 章全球年龄相关性黄斑变性市场细分分析，按产品，2018-2030 年（百万美元），患者份额（%）

  • 全球年龄相关性黄斑变性市场：产品变异分析
  • Eylea
  • Lucentis
  • Beovu
  • 其他

5. 2018-2030 年全球年龄相关性黄斑变性市场细分分析，按疾病类型（百万美元）

  • 全球年龄相关性黄斑变性市场：疾病类型的变异分析
  • 干性 AMD
  • 湿性 AMD

6. 2018-2030 年全球年龄相关性黄斑变性市场细分分析，按分销渠道（百万美元）

  • 全球年龄相关性黄斑变性市场：分销渠道的变化分析
  • 医院药房
  • 专业药房
  • 网上药店

7. 年龄相关性黄斑变性市场：细分分析，按地区，2018-2030 年（百万美元）

  • 年龄相关性黄斑变性市场：按地区分列的变化分析
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 意大利
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲
      • 南非
      • 沙特阿拉伯
      • 阿拉伯联合酋长国

8 全球年龄相关性黄斑变性市场：竞争分析

  • 主要市场参与者的最新发展和影响分析
    • 重大交易和战略联盟分析
      • 新产品发布
      • 併购
      • 伙伴关係和合同
  • 公司分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 热图分析
  • 公司市场分析
  • 供应商情况
    • 主要经销商及渠道合作伙伴名单
    • 潜在最终用户列表
    • 2021 年主要参与者的市场份额分析
  • 2021年公司市场份额
    • 竞争仪錶盘分析
  • 民营企业
    • 主要初创企业名单
    • 区域网络图
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Novartis AG
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bayer AG
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Pfizer Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bausch Health Companies Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Regeneron Pharmaceuticals Inc.
      • 公司简介
      • 产品基准
      • 战略举措
    • Amgen Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
    • Biogen
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Samsung Bioepis
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-4-68039-971-3

Age-related Macular Degeneration Market Growth & Trends:

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, according to a new study by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2022 to 2030. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

  • By product, eylea accounted for the largest revenue share in 2021 owing to the higher market penetration and patent protection. Beovu is anticipated to be the fastest-growing segment over the forecast period due to patent protection and superior drying efficacy
  • By disease type, wet AMD held the largest share in 2021 owing to the availability of major anti-VEGF products including Eylea, Lucentis, and Beovu
  • North America held the largest market share in 2021 and is expected to dominate over the forecast period due to better reimbursement facilities and the high adoption of novel age-related macular degeneration drugs for the treatment
  • Based on distribution channel, specialty pharmacy is expected to be the fastest-growing segment during the forecast period owing to increasing collaboration of manufacturers with specialty pharmacies for distributing their products

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation
    • 1.1.1 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR'S internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
    • 1.3.6 List of primary sources
  • 1.4 Information or data analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country - wise market estimation using bottom - up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Abbreviations
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
  • 3.2 Regulatory framework
  • 3.3 Penetration and Growth Prospect Mapping
  • 3.4 Pipeline Analysis, by Phase
    • 3.4.1 Key upcoming products
  • 3.5 Market Dynamics
    • 3.5.1 Market driver analysis
    • 3.5.2 Market restraint analysis
  • 3.6 PESTEL Analysis
  • 3.7 Quality Analysis of the market based route of administration
    • 3.7.1 Intravitreal
    • 3.7.2 Others
  • 3.8 Epidemiology Analysis
  • 3.9 Unmet Need Analysis

Chapter 4 Global Age - Related Macular DegenerationMarket - Segment Analysis, By Product, 2018 - 2030 (USD Million), Patient Share (%)

  • 4.1 Global Age - Related Macular DegenerationMarket: Product Movement Analysis
  • 4.2 Eylea
    • 4.2.1 Eyleaage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
  • 4.3 Lucentis
    • 4.3.1 Lucentisage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
  • 4.4 Beovu
    • 4.4.1 Beovuage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)
  • 4.5 Others
    • 4.5.1 Othersage - related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million), Patient Share (%)

Chapter 5 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Disease Type, 2018 - 2030 (USD Million)

  • 5.1 Global Age - Related Macular DegenerationMarket: Disease Type Movement Analysis
  • 5.2 Dry AMD
    • 5.2.1 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Wet AMD
    • 5.3.1 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Global Age - Related Macular DegenerationMarket - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1 Global Age - Related Macular DegenerationMarket: Distribution Channel Movement Analysis
  • 6.2 Hospital Pharmacy
    • 6.2.1 Hospital Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Specialty Pharmacy
    • 6.3.1 Specialty Pharmacymarket estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Online Pharmacy
    • 6.4.1 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Age - Related Macular DegenerationMarket: Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 7.1 Age - Related Macular DegenerationMarket: Regional Movement Analysis
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Spain
      • 7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Italy
      • 7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 South Korea
      • 7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.3 Mexico
      • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.4 Argentina
      • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East & Africa
      • 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.2 South Africa
      • 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.3 Saudi Arabia
      • 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.5.5 United Arab Emirate
      • 7.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Global Age - Related Macular DegenerationMarket: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 Major deals & strategic alliances analysis
      • 8.1.1.1 New Product Launches
      • 8.1.1.2 Mergers and Acquisitions
      • 8.1.1.3 Partnerships & Agreements
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
    • 8.2.3 Emerging Players
    • 8.2.4 Heat Map Analysis
  • 8.3 Company Market Position Analysis
  • 8.4 Vendor Landscape
    • 8.4.1 List of Key Distributors and Channel Partners
    • 8.4.2 List of Potential End Users
    • 8.4.3 Key Company Market Share Analysis, 2021
  • 8.5 Company Market Share, 2021
    • 8.5.1 Competitive Dashboard Analysis
  • 8.6 Private Companies
    • 8.6.1 List of Key Emerging Companies
    • 8.6.2 Regional Network Map
  • 8.7 Company Profiles
    • 8.7.1 F. Hoffmann - La Roche Ltd.
      • 8.7.1.1 Company overview
      • 8.7.1.2 Financial performance
      • 8.7.1.3 Product benchmarking
      • 8.7.1.4 Strategic initiatives
    • 8.7.2 Novartis AG
      • 8.7.2.1 Company overview
      • 8.7.2.2 Financial performance
      • 8.7.2.3 Product benchmarking
      • 8.7.2.4 Strategic initiatives
    • 8.7.3 Bayer AG
      • 8.7.3.1 Company overview
      • 8.7.3.2 Financial performance
      • 8.7.3.3 Product benchmarking
      • 8.7.3.4 Strategic initiatives
    • 8.7.4 Pfizer Inc.
      • 8.7.4.1 Company overview
      • 8.7.4.2 Financial performance
      • 8.7.4.3 Product benchmarking
      • 8.7.4.4 Strategic initiatives
    • 8.7.5 Bausch Health Companies Inc.
      • 8.7.5.1 Company overview
      • 8.7.5.2 Financial performance
      • 8.7.5.3 Product benchmarking
      • 8.7.5.4 Strategic initiatives
    • 8.7.6 Regeneron Pharmaceuticals Inc.
      • 8.7.6.1 Company overview
      • 8.7.6.2 Product benchmarking
      • 8.7.6.3 Strategic initiatives
    • 8.7.7 Amgen Inc.
      • 8.7.7.1 Company overview
      • 8.7.7.2 Financial performance
      • 8.7.7.3 Product benchmarking
    • 8.7.8 Biogen
      • 8.7.8.1 Company overview
      • 8.7.8.2 Financial performance
      • 8.7.8.3 Product benchmarking
      • 8.7.8.4 Strategic initiatives
    • 8.7.9 Samsung Bioepis
      • 8.7.9.1 Company overview
      • 8.7.9.2 Financial performance
      • 8.7.9.3 Product benchmarking
      • 8.7.9.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Age-Related Macular DegenerationMarket, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 5 Global Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 6 GlobalAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 8 North America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 9 North America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 11 U.S. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 12 U.S.Age-Related Macular DegenerationMarket, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Canada Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 14 Canada Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 17 Europe Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 20 Germany Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 U.K. Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 23 U.K. Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 24 U.K.Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 26 France Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 29 Italy Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 30 ItalyAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 32 Spain Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 33 SpainAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 35 Asia Pacific Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Asia PacificAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Age-Related Macular DegenerationMarket, By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 38 Japan Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 39 JapanAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 China Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 41 China Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 42 China Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 India Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 44 India Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 45 India Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 South Korea Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 47 South Korea Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 48 South Korea Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Australia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 50 Australia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 51 Australia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Latin America Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 53 Latin America Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 54 Latin America Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Brazil Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 56 Brazil Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 57 BrazilAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 Mexico Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 59 Mexico Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 60 MexicoAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Argentina Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 62 Argentina Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 63 ArgentinaAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Middle East & Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 65 Middle East & Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 66 Middle East & Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Saudi Arabia Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 68 Saudi Arabia Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 69 Saudi Arabia Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 South Africa Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 71 South Africa Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 72 South Africa Age-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 UAE Age-Related Macular DegenerationMarket,By Product, 2018 - 2030 (USD Million) (Patient Share in %)
  • Table 74 UAE Age-Related Macular DegenerationMarket, By Disease Type, 2018 - 2030 (USD Million)
  • Table 75 UAEAge-Related Macular DegenerationMarket, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Age-Related Macular Degenerationmarket segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Age-Related Macular Degenerationmarket snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Age related macular degenerationmarket driver impact
  • Fig. 14 Age related macular degenerationmarket restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's
  • Fig. 17 Strategy mapping
  • Fig. 18 Age-Related Macular Degenerationmarket: Product outlook and key takeaways
  • Fig. 19 Age-Related Macular Degenerationmarket: Product movement analysis & market share 2021 & 2030
  • Fig. 20 Eyleaage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million) (Patient Share in %)
  • Fig. 21 Lucentisage Related Macular Degenerationmarket estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
  • Fig. 22 Beovu age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
  • Fig. 23 Others age Related Macular Degeneration market estimates and forecast, 2018 - 2030 (USD Million)(Patient Share in %)
  • Fig. 24 Age-Related Macular Degenerationmarket: Disease type outlook and key takeaways
  • Fig. 25 Age-Related Macular Degenerationmarket: Disease Type movement analysis & market share 2021 & 2030
  • Fig. 26 Dry AMD market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Wet AMD market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Age-Related Macular Degenerationmarket: Distribution channel movement analysis & market share 2021 & 2030
  • Fig. 29 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Specialty Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Opioids: Regional outlook and key takeaways
  • Fig. 33 Regional outlook, 2021 & 2030
  • Fig. 34 North America
  • Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 U.S.
  • Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Canada
  • Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Europe
  • Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 U.K.
  • Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Germany
  • Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 France
  • Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Italy
  • Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Spain
  • Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific
  • Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Japan
  • Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • Fig. 56 China
  • Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 India
  • Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea
  • Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Australia
  • Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America
  • Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil
  • Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina
  • Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Middle East & Africa
  • Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa
  • Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia
  • Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 UAE
  • Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Market differentiators
  • Fig. 81 Key company market share analysis, 2021
  • Fig. 82 Company market position analysis
  • Fig. 83 Competitive dashboard analysis
  • Fig. 84 Regional network map